NASDAQ:CELU Celularity Q1 2025 Earnings Report $2.26 +0.15 (+7.11%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.27 +0.01 (+0.44%) As of 09/9/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Celularity EPS ResultsActual EPS-$1.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACelularity Revenue ResultsActual Revenue$5.74 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACelularity Announcement DetailsQuarterQ1 2025Date8/29/2025TimeAfter Market ClosesConference Call DateFriday, August 29, 2025Conference Call Time12:00AM ETUpcoming EarningsCelularity's Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Monday, November 10, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Celularity Earnings HeadlinesWBB Securities Upgrades Celularity (CELU)1 hour ago | msn.comCelularity (NASDAQ:CELU) Upgraded to Buy at WBB Securities2 hours ago | americanbankingnews.com“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druckenmiller — just raised nearly $1 billion in funding. Early backers believe it could be one of the most impactful breakthroughs of our lifetime. Whitney Tilson calls it “Helios” — and says a tiny Massachusetts firm sits at the center of what could become a global investment megatrend. If he’s right, this could mark the start of a seismic shift in how the world powers its future. | Stansberry Research (Ad)Celularity (NASDAQ:CELU) Cut to "Sell" at Wall Street ZenSeptember 8 at 2:49 AM | americanbankingnews.comCelularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) ComplianceSeptember 3, 2025 | globenewswire.comCelularity Second Quarter 2025 Earnings: US$1.02 loss per share (vs US$0.30 loss in 2Q 2024)August 31, 2025 | finance.yahoo.comSee More Celularity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email. Email Address About CelularityCelularity (NASDAQ:CELU) is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens. The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells. Among its lead investigational candidates is a placental-derived NK cell therapy being evaluated in both oncology and immuno-infectious disease settings. Celularity also explores exosome-based approaches to deliver therapeutic proteins and RNA payloads to specific tissues. Founded by Dr. Robert L. Hariri—who previously established and led Celgene’s cellular therapeutic research efforts—Celularity went public in April 2021 via a special purpose acquisition company (SPAC) transaction and now trades on the Nasdaq under the symbol CELU. The company is headquartered in Florham Park, New Jersey, with research and manufacturing operations designed to support scalable production of its cell therapy candidates. Under the leadership of President and Chief Executive Officer Robert L. Hariri, M.D., Ph.D., Celularity brings together a team of experts in cell biology, process development and clinical research. The company maintains collaborations with academic centers and industry partners to advance its portfolio through clinical trials, with the goal of delivering novel, off-the-shelf therapies to patients worldwide.Written by Jeffrey Neal JohnsonView Celularity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why DocuSign Could Be a SaaS Value Play After Q2 EarningsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Upcoming Earnings Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
